EP4326351A1 - Pansement à base de nanofibres - Google Patents

Pansement à base de nanofibres

Info

Publication number
EP4326351A1
EP4326351A1 EP21938076.3A EP21938076A EP4326351A1 EP 4326351 A1 EP4326351 A1 EP 4326351A1 EP 21938076 A EP21938076 A EP 21938076A EP 4326351 A1 EP4326351 A1 EP 4326351A1
Authority
EP
European Patent Office
Prior art keywords
wound dressing
solution
dressing according
production method
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP21938076.3A
Other languages
German (de)
English (en)
Other versions
EP4326351A4 (fr
Inventor
Ahmet Melikoglu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP4326351A1 publication Critical patent/EP4326351A1/fr
Publication of EP4326351A4 publication Critical patent/EP4326351A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/01—Non-adhesive bandages or dressings
    • A61F13/01008—Non-adhesive bandages or dressings characterised by the material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/225—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces

Definitions

  • the invention refers to a nanofiber solid, flexible and permeable wound dressing formed for cosmetic purposes or for the treatment of open wounds.
  • Hydrocoil another wound dressing used in the technique, is a self-adhesive absorbent hydrocolloid wound dressing with a semi-permeable covering layer that is impermeable to microorganisms and water. Hydrocolloids turn into gel when they come into contact with wound discharge. They create a moist environment that provides a triggering effect on granulation and epithelization. This type of dressing, on the other hand, does not have an effect to remove the wound discharge from the environment since it is semi-permeable.
  • Foam wound care products generally use polyurethane, which absorbs exudate, as a raw material and does not contain a wound healing component. In this case, there should be no infection on the wound to use the mentioned wound dressing. Moreover, because the fully permeable structure is not provided, the wound discharge cannot be removed from the environment.
  • biocompatible PVA-gelatin core-shell composite nanofiber tissue scaffold consisting of Polyvinyl Alcohol (PVA or P) and bovine gelatin (GE) to be used as a supportive material in wound and burn treatments is produced using the electrospinning method with environmentally sound green production approach.
  • the tissue must be completely free of bacteria to use the subject product. It is not suitable for bacteria-contaminated or infected wounds. Apart from this, it does not have any controlled molecule release feature.
  • the wound dressings which contain polylactic acid (PLA), a polymer such as polycaprolactone (PCL) and chitosan are obtained by electrospinning method. While PCL is used with the core-shell structure in the application number TR201517118, PLA is used in the patent application number TR201617649.
  • PLA polycaprolactone
  • the present invention refers to a wound dressing that meets the aforementioned requirements, eliminates all disadvantages and brings some additional advantages.
  • the primary purpose of the invention is to obtain a biocompatible wound dressing with self melting property of the dressing on the wound. Thanks to the formation of a wound dressing from the molecules that are good for the wound, the wound dressing disappears in the wound and it is not required to remove it from the wound. This provides an easy-to-use feature. Moreover, because it is not required to remove the wound dressing, which is the subject of this invention, from the wound, adhesion to the other wound and deformation, which is caused by that, on the skin can be prevented.
  • Another purpose of the invention is to provide wound dressing with a controlled releasing.
  • the spontaneous disappearance time of the wound dressing which is the subject of the invention, can be adjusted and it will make contributions to the rapid healing of the wound because it will release antimicrobial components into the wound environment in a controlled manner.
  • a purpose of the invention is to eliminate the need for wound cleaning before application, thanks to the antibacterial agents in its content such as PHMB and chitosan. While it quickly contributes to wound healing, it also prevents the biofilm formation. Prevention of the biofilm created by bacteria on the wound surface is very important for wound healing.
  • Another purpose of the invention is to obtain a nanofiber textured fully permeable wound dressing thanks to the electrospinning method used in production. In this way, while it removes the fluid formed in the wound from the environment, it also accelerates the wound healing process thanks to its air permeability.
  • nanofiber solid, flexible and permeable wound dressing formed for cosmetic purposes or for the treatment of open wounds is developed.
  • Figure-1 shows the SEM image of the wound dressing, which is a preferred arrangement of the invention and prepared with A, B, C and D solutions.
  • nanofiber wound dressing which is selected individually or as a combination from the group of polyvinyl alcohol, polyvinyl acetate and hydrolyzed collagen, chitosan, Poloxamer 188, polyhexanide for cosmetic or medical use.
  • the most fundamental component of the invention is a solution containing polyvinyl alcohol (PVA), polyvinyl acetate (PCA) and water.
  • This solution is called solution A throughout the invention for an easy understandability.
  • Table 1 shows the raw materials in solution A and a preferred amount of these raw materials that can be used in solution.
  • Solution A should be used to create a nanofiber wound dressing with the electrospinning device.
  • PVA and PCA which are used in the solution, have a structure that can spin the desired molecule in the magnetic field of the electrospinning device and retain it back into the nanofiber structure.
  • the ratio of PVA and PCA allows to decide how long the molecules that provides healing and are desired to be used will perform a controlled release.
  • Table 1 Table showing the raw materials in the content of solution A
  • solution A and one or more solutions selected from the solution group - solution B, solution C and solution D - which are explained in detail below are used.
  • Solution B consists of natural or synthetic polymer and water.
  • the purpose of using natural or synthetic polymers in the solution is to obtain nanofiber composites.
  • Table 2 below shows the natural or synthetic polymers that can be used in solution.
  • Hydrolyzed collagen is preferably used in the invention.
  • the subject hydrolyzed collagen may preferably be type I, type II or type III.
  • Type I and type III which are the most suitable options for tissue and subcutaneous, are preferably preferred in the invention.
  • Hydrolyzed collagen is used to support the existing collagen structure in the hypodermis layer under the skin. It is referred to as solution B for an easy understanding throughout the invention.
  • Table 3 shows the raw materials in solution B and a preferred amount of these raw materials that can be used in solution.
  • Solution C is a solution consisting of a natural or synthetic polymer, a solvent that dissolves the said polymer and water.
  • Said natural or synthetic polymer can be selected from those mentioned in Table 2.
  • chitosan Poly-D-Glucosamine
  • acetic acid solution is preferred as a solvent for solution C.
  • Chitosan can be dissolved in acetic acid. If another polymer is used, it is necessary to use another solvent. Chitosan is preferred because it prevents the formation of bacteria on the surfaces where it has contact, helps to eliminate harmful bacteria and has antibacterial properties. It is important to use chitosan within the specified range as it can affect the nanofiber structure. It is referred to as solution C for an easy understanding throughout the invention. Table 4 shows the raw materials in solution C and a preferred amount of these raw materials that can be used in solution.
  • Table 4 Table showing the raw materials in the content of solution C
  • Solution D is a solution consisting of a wound care molecule and water.
  • poloxamer 188 Kerphor P 188
  • polyhexanide Polyhexamethylene Biguanide PHMB
  • Solution D for an easy understanding throughout the invention.
  • Table 5 shows the raw materials in solution D and a preferred amount of these raw materials that can be used in solution.
  • the solution A and, in addition to solution A, one or more solution which is selected among solution B, solution C and solution D can be combined to obtain a wound dressing.
  • 50-99% Solution A can be used.
  • the mentioned solution C is used at a maximum rate of 15% in the mixture.
  • Another preferred arrangement of the invention is obtained by applying electro spinning method to 80% Solution A, 5% Solution B, 5% Solution C and 10% Solution D.
  • Figure-1 shows the SEM image of the wound dressing, which is a preferred arrangement of the invention and prepared with solutions A, B, C and D via electrospinning.
  • the obtained wound dressing has a spider web structure as it can be seen in Figure-1 and the nanofiber structure can be seen in the SEM image.
  • Obtaining solution A Polyvinyl alcohol and Polyvinyl acetate are mixed with cold deionized water for 60 minutes in the proportions specified in Table 1 . Subsequently, the temperature is increased to a range between 50-95°C, preferably to 85°C, and the mixture is mixed until it becomes homogeneous in the mixer heater. The temperature of Polyvinyl alcohol mixture is an important parameter. Polyvinyl alcohol and polyvinyl acetate can be used in the range of 1-20% depending on the controlled release time of the desired wound care material.
  • Obtaining solution B Hydrolyzed collagen is dissolved in deionized water within the proportions specified in Table 3. It is mixed in a magnetic stirrer to be dissolved homogeneously.
  • Obtaining solution C Acetic acid is dissolved in deionized water within the proportions specified in Table 4. Chitosan is added to the solution in a sealed container and mixed in a mixer. The mixed solution C is then mixed in an ultrasonic bath to accelerate the dissolution and make the solution homogeneous.
  • a wound dressing solution which absolutely consists of solution A in a usable proportion, is prepared preferably with solution B, solution C and solution D.
  • the said composition is mixed for at least 1 hour to obtain a homogeneous structure. Then, it is mixed for about half an hour in an ultrasonic bath at a temperature which do not exceed 25°C.
  • the wound dressing solution which is taken into an injector, obtains its wound dressing form thanks to the electrospinning method via electrospinning device at a feeding speed of 1 ,5 ml/hour.
  • the solution which is formed at a certain speed, reaches adequately suitable magnetic field, it enters into the electronic spinning and glides through the magnetic field and splashes to the non-flammable/non-stick paper to form a nanofiber structure.
  • This application can be performed from 1 hour to 144 hours depending on the thickness of the wound care material. Voltage is 40kv.
  • the above mentioned process should be carried out at a temperature between 12-25°C.
  • the pH range that can be used for the wound dressing solution is 4.5-7, and the preferred pH range is 5-7. While the process is being carried out, the environment has 70% humidity.
  • the product can be sterilized optionally with the help of gamma or similar rays especially after it is produced.
  • the wound dressing obtained with solution A, B, C and D is indicated for the treatment of open wounds, burns or diabetic patients undergoing chronic wound treatment. This feature of the wound dressing puts itself to the class III, medical device class.
  • a cosmetic-class care mask can be obtained that is suitable for the face and skin.
  • a cosmetic-class face care mask is obtained by combining the solution A with the hyaluronate solution,
  • the product can be used as a surgical thread which is a wound covering and suture material.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne un pansement solide, flexible et perméable à base de nanofibres utilisé à des fins cosmétiques ou pour le traitement de plaies ouvertes.
EP21938076.3A 2021-04-22 2021-10-14 Pansement à base de nanofibres Withdrawn EP4326351A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR202106995 2021-04-22
PCT/TR2021/051048 WO2022225477A1 (fr) 2021-04-22 2021-10-14 Pansement à base de nanofibres

Publications (2)

Publication Number Publication Date
EP4326351A1 true EP4326351A1 (fr) 2024-02-28
EP4326351A4 EP4326351A4 (fr) 2024-10-16

Family

ID=83723109

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21938076.3A Withdrawn EP4326351A4 (fr) 2021-04-22 2021-10-14 Pansement à base de nanofibres

Country Status (2)

Country Link
EP (1) EP4326351A4 (fr)
WO (1) WO2022225477A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117230554A (zh) * 2023-08-11 2023-12-15 苏州大学 一种抗菌纱线及其制备方法
CN119113179B (zh) * 2024-09-13 2025-02-25 苏州术数医疗科技有限公司 一种基于纳米材料的术后伤口智能愈合贴片制备方法
US20260098359A1 (en) * 2024-10-08 2026-04-09 Nano And Advanced Materials Institute Limited Quasi-permanent charge-bearing nanofiber and method of forming thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268345B2 (en) * 2008-09-03 2012-09-18 Transdermal Innovations Inc. Multipurpose hydrogel compositions and products
DE102012007307A1 (de) * 2012-04-13 2013-10-17 Carl Freudenberg Kg Hydrogelierende Fasern sowie Fasergebilde
JP6248293B2 (ja) * 2013-05-31 2017-12-20 株式会社Ａｋマネジメント 美容用キット
EP2896396A1 (fr) * 2014-01-20 2015-07-22 Abem Kimya Tibbi Malzemeler Yönetim Danismanligi Temizlik Servis Hizmetleri Sanayi Ve Dis Ticaret Limited Sirketi Formulation à base de plantes médicinales topiques pour le traitement des plaies topiques
CA2974209A1 (fr) * 2015-02-06 2016-08-11 Aziz Ghahary Systeme de substitut tissulaire artificiel

Also Published As

Publication number Publication date
EP4326351A4 (fr) 2024-10-16
WO2022225477A1 (fr) 2022-10-27

Similar Documents

Publication Publication Date Title
RU2468129C2 (ru) Биополимерное волокно, состав формовочного раствора для его получения, способ приготовления формовочного раствора, полотно биомедицинского назначения, способ его модификации, биологическая повязка и способ лечения ран
Shahriari-Khalaji et al. Cotton-based health care textile: A mini review
RU2369408C2 (ru) Гемостатическая композиция, включающая гиалуроновую кислоту
CN102417734B (zh) 一种氧化海藻酸钠/明胶可降解水凝胶及其制备方法
AU2002365662B2 (en) Wound dressings
CA2928336C (fr) Biomateriaux de collagene bioactif et methodes de fabrication
EP4326351A1 (fr) Pansement à base de nanofibres
US10293075B2 (en) Ready-to-use, hydrophilic, self-dispersive, fragmentable and biodegradable porous sponge matrix and a method of manufacturing thereof
WO1998057676A1 (fr) Matiere de recouvrement de plaie contenant de la fibroine de soie et de la sericine de soie comme composants principaux et son procede de production
CN107519524B (zh) 一种聚己内酯/胶原蛋白/季铵盐静电纺丝复合纤维膜及其制备方法
Mani et al. Sustainable electrospun materials with enhanced blood compatibility for wound healing applications—A mini review
JP5394600B2 (ja) 吸収性医科用合成コーティング材料、その製法およびその医学的使用
RU135921U1 (ru) Гемостатическое медицинское изделие
KR20070118730A (ko) 보습성이 우수한 창상피복재 및 그의 제조방법
RU2596502C2 (ru) Биоразлагаемый нетканый материал для медицинских целей
CN112807475A (zh) 一种高透气性可降解的载药皮肤创伤敷料及其制备方法
Tamilarasi et al. Electrospun scaffold-based antibiotic therapeutics for chronic wound recovery
US20120282320A1 (en) Hemostatic dressing
RU2240140C2 (ru) Медицинская многослойная повязка и изделия на ее основе
CN108939136B (zh) 一种用于鼻部填充止血的敷料及其制备方法
TR2021006995A1 (tr) Nanofiber Bir Bakım Örtüsü
CN108042839A (zh) 一种壳聚糖复合物创口贴及其制备方法
RU2847556C1 (ru) Железосодержащее аэрогельное гемостатическое средство на основе альгината натрия и хитозана
JPH0442019B2 (fr)
RU2827960C1 (ru) Гемостатический раствор, гемостатическое изделие и способ его изготовления

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20231121

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240916

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/30 20060101ALI20240910BHEP

Ipc: A61F 13/02 20240101ALI20240910BHEP

Ipc: A61L 15/00 20060101AFI20240910BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20250623

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20251024